A Single-arm, Multi-center Phase II Trial of Bendamustine/Rituximab Induction Followed by Venetoclax and Rituximab Consolidation for the Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 07 Aug 2019 Planned End Date changed from 31 Dec 2025 to 1 Dec 2025.
- 07 Aug 2019 Planned primary completion date changed from 31 Dec 2021 to 1 Dec 2021.
- 07 Aug 2019 Status changed from not yet recruiting to recruiting.